Ascendis Pharma A (ASND) Long-Term Debt Repayments (2023 - 2026)

Ascendis Pharma A has reported Long-Term Debt Repayments for 4 years, with the latest figure at -$10.0 million in Q1 2026.

• Quarterly Long-Term Debt Repayments fell 211.47% year-over-year to -$10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.9 million (down 155.16% YoY) and the FY2025 annual result came in at -$25.6 million, down 110.46% from the prior year.
• Long-Term Debt Repayments slipped to -$10.0 million in Q1 2026 per ASND's latest filing, from -$8.0 million in the prior quarter.
• Over five years, Long-Term Debt Repayments peaked at -$2.7 million in Q2 2023 and troughed at -$10.0 million in Q1 2026.
• A 4-year average of -$4.5 million and a median of -$3.1 million in 2024 frame the typical range for Long-Term Debt Repayments.
• The sharpest annual moves came in 2025 and 2026: Long-Term Debt Repayments fell 6.56% in 2025, then sank 211.47% in 2026.
• Over 4 years, Long-Term Debt Repayments stood at -$2.9 million in 2023, then dropped by 7.02% to -$3.1 million in 2024, then plunged by 152.61% to -$8.0 million in 2025, then decreased by 26.27% to -$10.0 million in 2026.
• According to Business Quant data, Long-Term Debt Repayments over the past three periods registered -$10.0 million, -$8.0 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.